

## Management of chronic kidney disease: The current novel and forgotten therapies

Ákos Géza Pethő<sup>a,\*</sup>, Mihály Tapolyai<sup>b,c</sup>, Éva Csongrádi<sup>d</sup>, Petronella Orosz<sup>e,f</sup>

<sup>a</sup> Faculty of Medicine, Semmelweis University, Department of Internal Medicine and Oncology, Budapest, Hungary

<sup>b</sup> Medicine Service, Ralph H. Johnson VA Medical Center, Charleston, SC, USA

<sup>c</sup> Department of Nephrology, Szent Margit Kórház, Budapest, Hungary

<sup>d</sup> Faculty of Medicine, University of Debrecen, Debrecen, Hungary

<sup>e</sup> Bethesda Children's Hospital, 1146 Budapest, Hungary

<sup>f</sup> Department of Pediatrics, Faculty of Medicine, University of Debrecen, 4032 Debrecen, Hungary

### ARTICLE INFO

#### Keywords:

Bone  
Chronic kidney disease  
Cardiovascular morbidity  
Complications of chronic kidney disease  
Diabetes  
Hypertension  
Nephrological care  
Slowing of progression  
Renal replacement therapy

### ABSTRACT

Chronic kidney disease (CKD) is a progressive and incurable condition that imposes a significant burden on an aging society. Although the exact prevalence of this disease is unknown, it is estimated to affect at least 800 million people worldwide. Patients with diabetes or hypertension are at a higher risk of developing chronic kidney damage. As the kidneys play a crucial role in vital physiological processes, damage to these organs can disrupt the balance of water and electrolytes, regulation of blood pressure, elimination of toxins, and metabolism of vitamin D. Early diagnosis is paramount to prevent potential complications. Treatment options such as dietary modifications and medications can help slow disease progression. In our narrative review, we have summarized the available therapeutic options to slow the progression of chronic kidney disease. Many new drug treatments have recently become available, offering a beacon of hope and optimism in CKD management. Nonetheless, disease prevention remains the most critical step in disease management. Given the significant impact of CKD on public health, there is a pressing need for further research. With the development of new technologies and advancements in medical knowledge, we hope to find more effective diagnostic tools and treatments for CKD patients.

### Introduction

Chronic kidney disease (CKD) is a prevalent condition that substantially affects both the patient and their immediate surroundings and poses a significant burden on the healthcare system. CKD affects approximately 800 million individuals worldwide [1,2]. Kidney Disease Improving Global Outcomes (KDIGO) guidelines recommend that glomerular filtration rate (GFR) measurement or estimation is a critical diagnostic tool for CKD [3]. Early diagnosis and management of CKD are crucial to prevent disease progression and minimize the risk of adverse outcomes. Accurate GFR assessment is critical in this regard, as it provides valuable information about the severity and progression of CKD. GFR measurement or estimation is widely recognized as significant in CKD diagnosis and management and is essential in clinical practice guidelines [4]. The five-stage classification system based on GFR levels

provides a framework for clinicians to assess CKD severity and tailor management strategies accordingly (Table 1).

Many diseases and potentially toxic damaging agents play a role in CKD development. However, irreversible glomerular and tubular damage develops during CKD pathogenesis, which can be predicted using several biochemical markers [5]. In the initial stage of CKD, albuminuria is the most readily available and best standardized urinary biomarker and is cost-effective with urine dipstick methods. Albuminuria is a predictor of CKD and further increases the cardiovascular risk [4,6]. Therefore, it is recommended that proteinuria levels be divided into stages (Table 2.) Cardiovascular risk also depends on the proteinuria level. Chronic kidney damage can be diagnosed if abnormal kidney function persists for at least three months, as well as in the case of abnormal albuminuria detected despite normal kidney function. CKD is also apparent in structural or morphological abnormalities of the

\* Corresponding author at: Faculty of Medicine, Semmelweis University, Department of Internal Medicine and Oncology, Hungary.

E-mail addresses: [petho.akos@semmelweis.hu](mailto:petho.akos@semmelweis.hu) (Á.G. Pethő), [mtapolyai@aol.com](mailto:mtapolyai@aol.com) (M. Tapolyai), [csongradi.eva@med.unideb.hu](mailto:csongradi.eva@med.unideb.hu) (É. Csongrádi), [orosz.petronella@bethesda.hu](mailto:orosz.petronella@bethesda.hu) (P. Orosz).

<https://doi.org/10.1016/j.jcte.2024.100354>

Received 18 April 2024; Received in revised form 16 May 2024; Accepted 21 May 2024

Available online 22 May 2024

2214-6237/© 2024 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

**Table 1**  
Stages of chronic kidney disease (CKD) based on estimated glomerular filtration rate (eGFR).

CKD stages	Description	eGFR (ml/min/1.73 m <sup>2</sup> )
G1	Mild renal impairment with normal or reduced GFR	>90
G2	Kidney damage, slightly reduced GFR	between 60–89
G3a	Mildly to moderately reduced GFR	between 45–59
G3b	Moderately to severely reduced GFR	between 30–44
G4	Severely decreased GFR	between 15–29
G5	Renal failure	<15 (or renal replacement therapies)


**Table 2**  
Stages of proteinuria. (ACR: albumin/creatinine ratio, TPCR: total protein/creatinine ratio).

Stadiums of albuminuria and proteinuria	Proteinuria (mg/day)		Urine protein/creatinine ratio		Description
	albuminuria	proteinuria	ACR	PCR	
A1	<30	<150	<3	<15	normal/ slightly elevated
A2	30–300	150–500	3–30	15–50	moderately increased
A3	>300	>500	>30	>50	increased significantly

kidneys (e.g., polycystic kidney disease in adults) [3].

With advancing age, kidney function can gradually decrease physiologically; the average rate of this is 0.8 ml/min/1.73 m<sup>2</sup> per year. However, it does not exceed the decrease in estimated glomerular filtration rate) of 4–5 ml/min per year [7]. Laboratory tests are commonly used to detect reduced kidney function in elderly individuals as this is a natural part of aging. CKD is characterized by scarring of the kidney tissue, leading to a decrease in healthy glomeruli. Along with global glomerulosclerosis, CKD can also damage tubules [8]. A gradual reduction in the number of nephrons has been identified as a significant contributor to the gradual narrowing of the glomerular filtration rate (GFR). The gradual exhaustion of adaptive mechanisms further exacerbates this phenomenon. Activation of the renin-angiotensin system, a key adaptation mechanism, causes systemic and intraglomerular hypertension, ultimately leading to glomerular damage. The oxidative stress that develops as a result of these processes further exacerbates this damage because reactive oxygen free radicals damage the ultrastructural structure. The cumulative effect of these processes eventually triggers a vicious cycle that further impairs kidney function [9,10].

As CKD progresses, the renal function gradually declines. Typical uremic symptoms are observed in patients with severely advanced and untreated kidney damage. Along with the gradual deterioration of kidney function, many accompanying clinical symptoms can be observed as a result of impaired physiological function of the kidneys (Fig. 1.).



**Fig. 1.** The decline of kidney function can have an impact on the entire body.

There are many methods for measuring the GFR. In clinical practice, measuring creatinine clearance requires accurate urine 24-hour collection. Creatinine clearance may overestimate the true GFR due to tubular secretion of creatinine. In 2009, the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula was introduced to estimate the GFR. There are also several inaccuracies in using estimated glomerular filtration rate (eGFR), such as natural GFR narrowing in old age and a significant loss of muscle mass associated with a decrease in serum creatinine level. A significantly reduced muscle mass may overestimate the eGFR [11,12]. In clinical practice, estimating a patient’s eGFR based on their serum creatinine levels is possible. However, an alternative method involves determining the serum levels of cystatin C, a marker that is freely filtered through the kidney and is not reabsorbed. The level of cystatin C in the patient’s serum is closely correlated with creatinine clearance. In cases where a patient’s eGFR value is unrealistically underestimated, and there is no evident kidney damage, the cystatin C level should be determined. This is especially important in cases where chronic kidney disease or albuminuria is suspected, or the patient is predisposed to such conditions. However, it is essential to note that cystatin C determination is unsuitable for use in acute kidney damage, systemic inflammatory conditions, and thyroid disease [13].

The recent introduction of novel drug therapies for chronic kidney disease (CKD) has led to the revision of international recommendations [14]. Our comprehensive narrative review underscores the importance of combining these new pharmacological interventions with established cost-effective and efficacious therapeutic modalities. It is imperative to recognize that a multi-faceted approach to CKD management is essential for optimal patient outcomes.

**Materials and methods**

Our review delves into current therapeutic procedures for treating chronic kidney disease. Although the latest international professional recommendations emphasize new therapeutic approaches, they do not negate the significance of the established treatment options. Hence, in addition to prevention, it is imperative to consider cost-effective and conveniently accessible treatment options that have demonstrated efficacy in arresting the advancement of chronic kidney disease. In our narrative review, we have provided an overview of the current treatment options. Our intention was not to present a comprehensive summary, as this has been covered extensively in other publications.

**Slowing the progression of chronic kidney disease**

Nephrological care involves two crucial tasks: preventing chronic kidney disease (CKD) and slowing its progression. Individuals with CKD have a significantly higher risk of morbidity and mortality from cardiovascular disease, regardless of whether they have diabetes or hypertension. Additionally, the risk of death from CKD, particularly from cardiovascular diseases, is higher than that required to start renal replacement therapy [15–17]. Therefore, it is imperative to prevent kidney disease and prevent the progression of CKD. Addressing the underlying conditions that cause CKD is essential to slowing its progression. For instance, treatment of Autosomal Polycystic Kidney Disease (ADPKD), diabetes, hypertension, primary glomerular diseases, and hematological diseases is recommended. The most straightforward approach to slowing kidney disease progression is promptly managing reversible processes, such as possible urine outflow obstruction.

*Non-drug treatment options*

Therefore, we must use dietary and medicinal options to slow disease progression. The possibility of slowing progression is significantly determined by the underlying disease and the patient’s cooperation. Dietary treatment practices are perhaps one of the most important factors in preventing the progression of chronic kidney damage [18]. A

fundamental aspect of maintaining good health is ensuring an adequate daily intake of fluids. It is evident that when one consumes a low amount of fluid, the kidneys need to concentrate the waste, leading to an increased burden when excreting all waste in a single liter of urine compared to three liters. However, avoiding fluid overload is imperative. To establish the amount of fluid required daily, it is most appropriate to ensure that there is no increase in body weight, which can be achieved by consuming an average of 2.0–2.5 L per day. There is ongoing debate concerning the optimal level of dietary protein intake, particularly concerning the reduction and extent of such intake. It is imperative to emphasize that an excessive decrease in protein intake may cause severe malnutrition and loss of muscle mass unless supplemented with ketoacid treatment. In general, it can be posited that clinical studies have demonstrated a reduction in the progression of CKD with a protein intake of 0.8 g/kg body weight/day [19]. The adoption of a low-salt diet not only promotes blood pressure regulation but also mitigates salt-water retention. It is recommended that the daily dietary sodium intake should not surpass 2–3 g or approximately 5 g of table salt. By adhering to this advice, individuals can significantly reduce their risk of developing hypertension and related cardiovascular conditions [18,20–22]. Reducing dietary salt intake does not apply sodium bicarbonate therapy to treat metabolic acidosis. Several published papers have confirmed that the administration of sodium bicarbonate does not significantly affect systemic blood pressure [23–25].

Other important nonpharmacological therapeutic options include a special diet. The first was a plant-based diet, which was an alkaline-rich “alkaline ash” diet. Conventional dietary guidelines for patients with CKD typically prioritize the quantity of nutrients consumed, potentially limiting the intake of fruits and vegetables. This reduction in consumption could result in a loss of opportunity to reap the benefits of higher fiber intake, such as modulation of the gut microbiota to reduce the production of uremic toxins. Additionally, a decrease in the intake of plant fats, such as olive oil, which has anti-atherogenic properties, and plant anions, which may alleviate metabolic acidosis and slow CKD progression, may also occur [26].

Another dietary option is a ketogenic diet. Ketogenic diets (KD) are popular and frequently used for weight loss. These high-fat, low-carbohydrate dietary approaches shift the body into ketosis, where the body primarily relies on fats and ketones for energy instead of carbohydrates. It has been suggested that KD could be considered a new strategy for managing and treating CKD [27].

Perhaps the most logical summarizing diet for healthy choices is the Mediterranean diet. The Mediterranean diet is positively associated with maintaining kidney function, improving the cardiometabolic profile, and reducing mortality risk in individuals diagnosed with CKD. This dietary pattern, characterized by high consumption of plant-based foods, whole grains, fish, and olive oil, and low intake of red and processed meats, has been shown to confer several health benefits. Recent studies have provided evidence of the effectiveness of the Mediterranean diet in managing CKD. Specifically, adherence to this diet is associated with a slower decline in kidney function and a lower risk of progression to end-stage renal disease. Additionally, this dietary pattern has been shown to improve lipid profile, glucose metabolism, and blood pressure in individuals with CKD, thereby reducing the risk of cardiovascular disease. Furthermore, the Mediterranean diet is associated with a lower risk of mortality in individuals with CKD. This is likely due to the beneficial effects of this dietary pattern on several health outcomes, including inflammation, oxidative stress, and endothelial function [28–30].

As CKD advances, the body’s uric acid level may increase. Nevertheless, it remains uncertain whether decreasing uric acid levels is effective in slowing the progression of CKD. Therefore, it is advisable to individually determine the treatment for hyperuricemia [31,32].

It is essential to understand that dietary and lifestyle changes should not replace medical treatments but complement them. Each diet has its advantages and disadvantages. To ensure that patients with CKD

maximize their health benefits, they should be provided with the necessary knowledge and resources to adopt a diet that best suits their specific needs and CKD stages.

### Angiotensin-converting enzyme inhibitors

The benefits of angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin II receptor blockers (ARBs) in reducing the risk of cardiovascular events (CVEs) and delaying end-stage kidney disease (ESKD) in patients with CKD are well established [33–35]. In cases where contraindications are absent, physicians may elect to use ACEIs in the treatment of hypertension, whereas ARBs are used in cases of intolerance [36]. In CKD, resistant hypertension is common and may necessitate the administration of multiple antihypertensive therapies [37]. For nearly three decades, ACEIs and ARBs have been known to reduce urinary protein excretion, exhibit a kidney-protective effect, and effectively slow CKD progression [38]. ACE inhibitors and ARBs not only decrease intra-glomerular pressure but also reduce the amount of primary ultrafiltrate, resulting in a decrease in the reabsorption burden of the tubular epithelium. This includes the fluid volume, electrolytes, and organic substances that need to be reabsorbed by the tubules. It is important to remember that ACEi does not change renal blood flow but improves the medullary blood supply (relatively). Fig. 2 summarizes the main effects of ACEIs/ARBa on kidneys. However, in specific cases, the use of these drugs may result in further deterioration of kidney function and elevated serum potassium levels, leading to the suspension of their use as blood pressure-lowering agents [39–41]. It is important to note that the renal protective effect is only valid in CKD with proteinuria [3].

It is essential to consider whether the use of ACE or ARB inhibitors should be stopped in cases of severe kidney damage. However, the discontinuation of these medications in patients with advanced CKD did not appear to improve kidney function significantly. Instead, it may increase the risk of CVEs and lead to a faster onset of kidney failure [42].

### Avoiding nonsteroidal anti-inflammatory drugs

Nonsteroidal anti-inflammatory drugs (NSAIDs) inhibit the production of prostaglandins in the kidneys by paralyzing cyclooxygenase enzymes (COX-1 and COX-2) in the body. This triggers vasoconstriction of the afferent arterioles, leading to worsening intraglomerular blood circulation. NSAIDs also cause salt retention, which can further increase the blood pressure. The long-term use of NSAIDs can cause permanent kidney damage, particularly in older patients. Therefore, the use of NSAIDs is recommended only for acute pathologies and their chronic use





Fig. 2. The already “classic” ACEi/ARB drugs exert their renal protective effect by reducing intraglomerular pressure. Abbreviations: ACE-I: angiotensin converting enzyme inhibitors.

should be avoided. The cumulative dose determines the complications that develop [43–45]. It is imperative to note that NSAIDs cannot be considered safe in individuals diagnosed with CKD. The use of NSAIDs in patients with CKD has been associated with significant adverse outcomes, such as renal papillary necrosis, acute kidney injury, and chronic kidney disease progression [45]. Therefore, alternative treatments should be considered [46,47].

*Use of sodium-glucose cotransporter-2 (SGLT2) inhibitors*

Sodium-glucose cotransporter-2 (SGLT2) inhibitors are key therapeutic options for nephrology and CKD treatment. In 2013, the US Food and Drug Administration (FDA) approved this drug for treating type 2 diabetes. These inhibitors are a group of medications used to lower the blood sugar levels. In addition to type 2 diabetes, they are commonly used to treat heart failure [48]. Sodium-glucose cotransporter 2 (SGLT2) inhibitors are pharmaceutical agents that inhibit glucose reabsorption in the proximal tubules of the kidneys, resulting in glucosuria (Fig. 3.). Additionally, SGLT2 inhibitors reduce sodium reabsorption, which leads to increased natriuresis and effectively represents a mild add-on diuretic effect [49]. Nevertheless, the entry of sodium into the macula densa was augmented, normalizing the tubuloglomerular feedback. Consequently, vasoconstriction of the afferent arteriole occurs, causing a reduction in intraglomerular pressure [50–52].

These effects provide new opportunities to inhibit the progression of CKD. Since the EMPA-Kidney and DAPA-CKD (EMPA-KIDNEY: Study of Heart and Kidney Protection With Empagliflozin, DAPA-CKD: Study to Evaluate the Effect of Dapagliflozin on Renal Outcomes and Cardiovascular Mortality in Patients With Chronic Kidney) studies, we know that SGLT2 inhibitors slow CKD progression even in non-diabetic and patients with proteinuria [3,18,53,54]. Guidelines recommend using SGLT2 inhibitors in patients with CKD with adequate RAAS inhibition based on 1B evidence [3]. The newly proposed KDIGO recommendation advocates the initiation of SGLT2 inhibitors for all CKD patients with an eGFR greater than 20 ml/min without any contraindications. This recommendation is based on the numerous beneficial effects of SGLT2 inhibitors and their potential to improve CKD patients’ overall health and well-being. Therefore, healthcare professionals must consider the potential advantages of SGLT2 inhibitors when treating patients with CKD, especially those with a well-preserved eGFR [14].



**Fig. 3.** The main therapeutic effect of SGLT2 inhibitors is the increased excretion of glucose and sodium, which, by starting other physiological processes, we can experience the beneficial effect of such treatment, for example, in heart failure or in slowing down the progression of CKD. Abbreviations: ATPase: Adenosine 5'-TriPhosphatase; Na, natrium; K, potassium; Glu, glucose; Glut2: Glucose transporter 2; SGLT2, sodium/glucose cotransporter 2.

*Glucagon-like Peptide-1 (GLP-1) receptor agonists*

Glucagon-like peptide-1 (GLP-1) receptor agonists represent a novel class of drugs for treating type 2 diabetes mellitus. These medications exert their pharmacological action by effectively inhibiting incretin production in the small intestine, reducing glucagon secretion and decelerating gastric emptying, ultimately leading to decreased appetite (Fig. 4.) [55]. Notably, GLP-1 receptor agonists have been found to elicit a favorable response in patients with chronic kidney disease (CKD), as evidenced by lowered insulin and glucose levels, as well as moderate blood pressure reduction and hunger [56]. Furthermore, these drugs may be critical in slowing CKD progression by reducing urinary albumin excretion, as observed in clinical studies [57].

According to the SUSTAIN 6 and LEADER clinical trials, GLP-1 receptor agonists exhibit a slower eGFR reduction than placebo controls. This effect was especially pronounced in patients with CKD whose baseline eGFR was less than 60 ml/min/1.73 m2. These findings suggest that GLP-1 receptor agonists may hold promise as therapeutic interventions for patients [18,58]. To date, clinical studies have confirmed the efficacy of GLP-1 analogs solely in patients with diabetes. Nonetheless, the newly released KDIGO recommendations advocate using GLP-1 analogs in the absence of contraindications because of their numerous favorable effects. This recommendation suggests that GLP-1 analogs could be appropriate for a wider range of patients than those with diabetes, promoting a more favorable metabolic environment and weight loss [14,59].

*Mineralocorticoid receptor blockade (MRA)*

Aldosterone is a steroid hormone that exhibits mineralocorticoid activity. It is synthesized in the zona glomerulosa of the adrenal cortex. Aldosterone facilitates sodium reabsorption in the renal system and promotes potassium excretion in the cortical collecting ducts. Recent studies have suggested that aldosterone and mineralocorticoid activation significantly contribute to the pathophysiology of cardiovascular and renal diseases [60]. The harmful effects of aldosterone on the heart include myocardial hypertrophy, ventricular remodeling, proarrhythmic effects, myocardial ischemia, and reduced blood flow in the coronary arteries (Fig. 5.). Aldosterone in the renal system may cause glomerular hypertrophy, glomerulosclerosis, proteinuria, and consequent kidney damage [61–63].

Adding aldosterone antagonists to ACEi/ARBs to reduce CKD progression can further reduce proteinuria; however, this also increases the risk of hyperkalemia. Patients who experience mild hyperkalemia due to ACEi/ARB use may concurrently present with mild metabolic acidosis known as non-anion gap metabolic acidosis (NAGMA). Therefore, these patients are potential candidates for NaHCO3 supplementation. Empirical evidence suggests that adding NaHCO3 can effectively ameliorate and reverse hyperkalemia. In contrast, nonsteroidal mineralocorticoid receptor blockers are more efficient and selective in reducing proteinuria and have a lower risk of hyperkalemia. Finerenone is a nonsteroidal MRA that reduces albuminuria and N-terminal pro-B-type natriuretic peptide (NT-proBNP) and does not cause hyperkalemia [18,64].

*Treatment of metabolic acidosis*

As chronic kidney disease (CKD) progresses, renal function declines, reducing the ability of the body to excrete H+ and reabsorb bicarbonate. This results in metabolic acidosis, which can lead to further cellular damage (Fig. 6) [65]. Metabolic disturbances are key contributors to the incidence of non-anion gap metabolic acidosis (NAGMA) in patients diagnosed with CKD. Specifically, decreased renal acid excretion, increased ammonia generation, and bicarbonate loss are notable factors. However, it is important to note that the source of NAGMA in CKD is not related to the factors mentioned earlier but rather to other metabolic processes. Fortunately, research has found that administering oral




Fig. 4. The use of GLP-1 analogs appears to have many other beneficial effects in addition to treating diabetes.




Fig. 5. The amelioration of aldosterone activity by reducing or inhibiting its function is highly beneficial to the cardiovascular system. In addition, it is an effective measure for slowing the progression of chronic kidney disease (CKD). Abbreviations: AP-1: Activator protein 1; MRA, mineralocorticoid receptor antagonist; NO, nitric oxide; NADPH, nicotinamide adenine dinucleotide phosphate oxidase; NF-κB: Nuclear factor kappa-light-chain-enhancer of activated B cells; ROS: Reactive oxygen species; SGK-1: Serine/threonine-protein kinase.


sodium bicarbonate is a straightforward and cost-effective method to slow the progression of CKD [66–68].

A method of providing a base and/or reducing dietary acid load can be implemented to treat metabolic acidosis and reduce its harmful effects. The latest recommendations suggest initiating base treatment when serum bicarbonate levels fall below or equal to 24 mEq/L to maintain total CO<sub>2</sub> levels between 24 and 26 mEq/L [69]. The extent to which urinary acidification cessation could represent an endpoint for CKD-controlling intervention methods aimed at prolonging renal survival is indeterminate.

*Use of Pentoxifylline*

Although Pentoxifylline is no longer frequently used, it has been shown to decelerate CKD progression. Pentoxifylline (PTF) is a methylxanthine derivative and non-specific phosphodiesterase inhibitor. Its mode of action involves the inhibition of cyclic-30,50-phosphodiesterase (PDE), which results in an elevation in the

intracellular concentration of cyclic adenosine monophosphate (cAMP) and the consequent activation of protein kinase A (PKA) [70,71]. This, in turn, enhances the microcirculation and induces potent hematopoietic properties. Pentoxifylline is known for its potent antiproliferative and anti-inflammatory properties, making it a highly beneficial medication. It is frequently prescribed to treat peripheral vascular diseases and CKD [72,73]. The recommended oral dose is 400 mg, administered twice or thrice daily with a meal. However, the specific dosage may vary depending on an individual’s medical needs. In 2012, a study was conducted to examine the effects of a specific medication on 91 patients over one year. The findings revealed that the drug successfully lowered the levels of high-sensitivity C-reactive protein (hs-CRP), tumor necrosis factor α (TNF-α), and fibrinogen in the blood [71]. Furthermore, it was observed that the eGFR increased by 2.4 mL/min/1.73 m<sup>2</sup>. Other studies have also indicated that this medication, PTF, improves kidney function in individuals with CKD and reduces proteinuria [74].



**Fig. 6.** Treating metabolic acidosis is a cost-effective and straightforward approach. Importantly, correcting metabolic acidosis has been shown to decelerate the progression of chronic kidney disease (CKD), emphasizing the significance of this clinical intervention. Abbreviations: CKD: chronic kidney disease; GFR: glomerular filtration rate; NH4: Ammonium.


**Treatment of renal anemia**

Renal anemia can occur in the early stages of CKD (stage 3a). Anemia leads to tissue hypoxia, contributing to further progression [75]. It is plausible that ameliorating anemia would improve oxygen delivery to the medulla. Renal anemia is caused by reduced erythropoietin production [76]. A diagnosis can be made if other causes, such as iron deficiency, are ruled out [77,78]. If the patient’s hemoglobin concentration is consistently below 11 g/dl (Htc < 0.33 %) and secondary causes of anemia can be ruled out, erythropoietin treatment should be initiated [3]. In contemporary medical practice, a wide range of medications are available to stimulate the production of red blood cells [79]. Human recombinant erythropoietin products are among these drugs. Hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI) agents are currently available for this purpose. These agents function by inhibiting the activity of hypoxia-inducible factor prolyl hydroxylase enzymes, leading to reversible inhibition that mimics the natural response of the body to hypoxia. As a result, the body’s natural process of red blood cell formation is activated [80]. It must be noted that these drugs are currently only accessible to dialysis patients [81] (e.g., Daprodustat, Vadadustat, Roxadustat) [82]. Normalization of the patient’s blood count is not recommended; the target hemoglobin range to be achieved is 11–12 g/dl. In addition to erythropoietin treatment, the body’s iron supply must be regularly monitored [3,18,83]. In some cases, erythropoietin resistance may develop after erythropoietin treatment. In such cases, we must rule out additional folic acid and vitamin B12 deficiencies in addition to possible iron deficiency. Uncorrected metabolic acidosis, chronic infections, and secondary hyperparathyroidism are the most common causes of erythropoietin resistance in patients with CKD.

*Ckd-metabolic bone disease*

Hyperphosphatemia is a common complication of chronic kidney disease (CKD). Phosphate retention begins in the early stages of CKD and contributes to the development of secondary hyperparathyroidism. Properly regulating mineral and bone metabolism relies on the function of various hormones that oversee the calcium and phosphate levels (Fig. 7.). These hormones consist of parathyroid hormone (PTH), calcidiol or 25 (OH)D3 (which is the precursor of calcitriol), calcitriol or 1,25 (OH)2D3 (the most potent form of the vitamin D hormone system), calcitonin, and FGF23/klotho.

These hormones play a significant role in maintaining bone health and metabolism. CKD can significantly alter various body parameters,



**Fig. 7.** Metabolic bone disease in chronic kidney disease (CKD) is a multifaceted autoregulatory disorder. Interventions must be enacted at several key points to address this condition. Treating metabolic bone disease in CKD necessitates a comprehensive approach that targets the underlying mechanisms contributing to the disease. Appropriate management of this complex condition requires a thorough understanding of the pathophysiological processes underlying metabolic bone disease in CKD. Abbreviations: PTH: parathyroid hormone; VDR: vitamin D receptor; FGFR1: Fibroblast growth factor receptor 1; FGF23: Fibroblast growth factor 23.

including calcium, phosphate, PTH, FGF23/Klotho, and the vitamin D hormonal system, encompassing calcidiol and calcitriol. These changes can affect bone and vascular metabolism, ultimately leading to adverse clinical outcomes such as decreased bone mass, increased fragility fractures, and vascular and valvular calcification [84]. Patients with CKD often experience disruptions in the regulation of healthy bone turnover. Achieving optimal laboratory values is essential for managing this condition and can be determined based on published results. For patients undergoing hemodialysis, the recommended laboratory ranges are phosphate levels between 3.6 to 5.2 mg/dl, calcium levels between 7.9 to 9.5 mg/dl, and parathyroid hormone (PTH) levels between 168 to

764 pg/ml. Notably, in hemodialysis, PTH levels are typically 2–9 times higher than the normal range [85].

In the case of a significant decrease in GFR, a bone density test alone is not sufficient to assess bone metabolism because it cannot differentiate between the bone metabolism differences characteristic of various kidney diseases, such as adynamic bone disease, osteitis fibrosa caused by secondary hyperparathyroidism, or osteomalacia. However, the assessment of bone metabolism in patients with early CKD (stages 1–2) is similar to that in a healthy population [86]. Starting with CKD stage 3a, calcium, phosphorus, alkaline phosphatase, parathyroid hormone, and 25-hydroxyvitamin D levels are recommended every 3–6 months [87]. Additional treatment options for bone and mineral metabolism disorders accompanying kidney disease include native vitamin D supplementation, active vitamin D/vitamin D receptor agonists (e.g., paricalcitol), and calcimimetic drugs (e.g., cinacalcet, etelcalcetide) applications [3,88,89]. Parathyroid resection may be considered an alternative treatment option when there is insufficient medical intervention. Research has demonstrated that this surgical procedure yields favorable long-term outcomes [90]. A new biological treatment offers hope for CKD-MBD treatment, particularly in osteoporosis patients. Denosumab is a receptor activator of nuclear factor- $\kappa$ B ligand (RANK-L) inhibitor that reduces bone resorption, impairs osteoclast formation and function, and increases bone mineral density. This novel treatment is particularly promising because it targets the underlying mechanisms of CKD-MBD, which can lead to serious complications, such as bone fractures and cardiovascular disease. By inhibiting RANK-L, denosumab effectively reduced the risk of these complications and improved patients' quality of life with CKD-MBD. As a result, this treatment has the potential to become a valuable addition to the current treatment options for CKD-MBD, offering a safe and effective alternative for patients who cannot tolerate other forms of treatment [91–93].

## Conclusions

In summary, timely recognition of chronic kidney damage is important for slowing down the progression and treating additional complications that develop in parallel with chronic kidney damage. Previously, only ACEI or ARB preparations could be used for kidney protection; non-steroidal MRAs, SGLT2 inhibitors, and GLP1 receptor agonists can also be used to slow the progression of chronic kidney disease. Cardiovascular death can also be reduced by treating the associated complications. In addition to drug treatment, the revision of dietary habits is helpful. The dosage of certain drugs must be adjusted in parallel with the reduction in kidney function. Prevention of CKD development of chronic kidney disease is vital. The treatment of chronic kidney disease requires a complex approach. If, despite therapeutic attempts, the progression of kidney disease cannot be slowed, such a patient must be prepared in time for kidney replacement treatment or, if suitable, placed on the kidney transplant waiting list.

**Institutional Review Board Statement:** Not applicable.

**Informed Consent Statement:** Not applicable.

## CRedit authorship contribution statement

Ákos Géza Pethő: Writing – original draft, Conceptualization. Mihály Tapolyai: Supervision. Éva Csongrádi: Supervision. Petronella Orosz: Visualization.

## Declaration of competing interest

The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: [The authors declare no conflicts of interest regarding the publication of this article. Dr. Tapolyai is an employee of the United States Veterans' Health Administration. However, the views and opinions expressed here do not reflect the official views or opinions of the United States Veterans

Health Administration and are not endorsed. MT and ÁGP contributed to the idea conception, search methods, paper retrieval, data extraction, and analysis. ÁGP wrote the first draft of the manuscript and coordinated the subsequent revisions. PO reviewed and edited the paper, developed figures, and made visual presentations. MT and ECs supervised the manuscript preparation. All authors have read and agreed to the published version of the manuscript].

## Data Availability Statement:

No data were created.

### Funding

This study received no external funding.

**Declaration of Generative AI and AI-assisted technologies in the writing process:** There was no use of AI-assisted technologies in the writing process, the manuscript is the intellectual property of the authors.

## References

- [1] A.L. Ammirati, Chronic Kidney Disease, *Rev Assoc Med Bras* (1992) 66Suppl 1 (2020) s03-s09.
- [2] Okpechi IG, Bello AK, Ameh OI, Swanepoel CR. Integration of Care in Management of CKD in Resource-Limited Settings. *Semin Nephrol* 2017;37:260–72.
- [3] KDIGO - Kidney Disease Improving Global Outcomes - Guidelines, 2023. ([www.kdigo.org/2023](http://www.kdigo.org/2023). Accessed on: 01/December/2023).
- [4] Chen TK, Knicely DH, Grams ME. Chronic Kidney Disease Diagnosis and Management: A Review. *JAMA* 2019;322:1294–304.
- [5] Han KH, Kim B, Ji SC, Kang HG, Cheong HI, Cho JY, et al. Mechanism of Chronic Kidney Disease Progression and Novel Biomarkers: A Metabolomic Analysis of Experimental Glomerulonephritis. *Metabolites* 2020;10.
- [6] Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. *Kidney Int Suppl.* 3(1) (2013) 1-150.
- [7] Poh N, de Lusignan S. Data-modelling and visualisation in chronic kidney disease (CKD): a step towards personalised medicine. *Inform Prim Care* 2011;19:57–63.
- [8] P. Drawz, M. Rahman, Chronic kidney disease, *Ann Intern Med* 162 (2015) ITC1-16.
- [9] Vassalotti JA, Centor R, Turner BJ, Greer RC, Choi M, Sequist TD, et al. National Kidney Foundation Kidney Disease Outcomes Quality. Practical Approach to Detection and Management of Chronic Kidney Disease for the Primary Care Clinician. *Am J Med* 2016;129:153–162 e157.
- [10] Said A, Desai C, Lerma EV. Chronic kidney disease. *Dis Mon* 2015;61:374–7.
- [11] Chowdhury R, Peel NM, Krosch M, Hubbard RE. Frailty and chronic kidney disease: A systematic review. *Arch Gerontol Geriatr* 2017;68:135–42.
- [12] Totoli C, Carvalho AB, Ammirati AL, Draibe SA, Canziani MEF. Associated factors related to chronic kidney disease progression in elderly patients. *PLoS One* 2019; 14:e0219956.
- [13] Inker LA, Schmid CH, Tighiouart H, Eckfeldt JH, Feldman HI, Greene T, et al. Estimating glomerular filtration rate from serum creatinine and cystatin C. *N Engl J Med* 2012;367:20–9.
- [14] C.K.D.W.G. Kidney Disease: Improving Global Outcomes, KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease, *Kidney Int* 105 (2024) S117-S314.
- [15] Sarnak MJ, Amann K, Bangalore S, Cavalante JL, Charytan DM, Craig JC, et al. Chronic Kidney Disease and Coronary Artery Disease: JACC State-of-the-Art Review. *J Am Coll Cardiol* 2019;74:1823–38.
- [16] Tonelli M, Wiebe N, Culleton B, House A, Rabbat C, Fok M, et al. Chronic kidney disease and mortality risk: a systematic review. *J Am Soc Nephrol* 2006;17: 2034–47.
- [17] Schiffrin EL, Lipman ML, Mann JF. Chronic kidney disease: effects on the cardiovascular system. *Circulation* 2007;116:85–97.
- [18] Kalantar-Zadeh K, Jafar TH, Nitsch D, Neuen BL, Perkovic V. Chronic kidney disease. *Lancet* 2021;398:786–802.
- [19] Kim SM, Jung JY. Nutritional management in patients with chronic kidney disease. *Korean J Intern Med* 2020;35:1279–90.
- [20] Kalantar-Zadeh K, Fouque D. Nutritional Management of Chronic Kidney Disease. *N Engl J Med* 2017;377:1765–76.
- [21] Akchurin OM. Chronic Kidney Disease and Dietary Measures to Improve Outcomes. *Pediatr Clin North Am* 2019;66:247–67.
- [22] Anderson CAM, Nguyen HA. Nutrition education in the care of patients with chronic kidney disease and end-stage renal disease. *Semin Dial* 2018;31:115–21.
- [23] Beynon-Cobb B, Louca P, Hoorn EJ, Menni C, Padmanabhan S. Effect of Sodium Bicarbonate on Systolic Blood Pressure in CKD: A Systematic Review and Meta-Analysis. *Clin J Am Soc Nephrol* 2023;18:435–45.
- [24] Kahle LE, Kelly PV, Eliot KA, Weiss EP. Acute sodium bicarbonate loading has negligible effects on resting and exercise blood pressure but causes gastrointestinal distress. *Nutr Res* 2013;33:479–86.

[25] Luft FC, Zemel MB, Sowers JA, Fineberg NS, Weinberger MH. Sodium bicarbonate and sodium chloride: effects on blood pressure and electrolyte homeostasis in normal and hypertensive man. *J Hypertens* 1990;8:663–70.

[26] Carrero JJ, Gonzalez-Ortiz A, Avesani CM, Bakker SJL, Bellizzi V, Chauveau P, et al. Plant-based diets to manage the risks and complications of chronic kidney disease. *Nat Rev Nephrol* 2020;16:525–42.

[27] Crosby L, Davis B, Joshi S, Jardine M, Paul J, Neola M, et al. Ketogenic Diets and Chronic Disease: Weighing the Benefits Against the Risks. *Front Nutr* 2021;8:702802.

[28] Podadera-Herreros A, Alcalá-Díaz JF, Gutierrez-Mariscal FM, Jimenez-Torres J, Cruz-Ares S, Arenas-de Larriva AP, et al. Long-term consumption of a mediterranean diet or a low-fat diet on kidney function in coronary heart disease patients: The CORDIOPREV randomized controlled trial. *Clin Nutr* 2022;41:552–9.

[29] Hansrivijit P, Oli S, Khanal R, Ghahramani N, Thongprayoon C, Cheungpasitporn W. Mediterranean diet and the risk of chronic kidney disease: A systematic review and meta-analysis. *Nephrology (Carlton)* 2020;25:913–8.

[30] Hu EA, Coresh J, Anderson CAM, Appel LJ, Grams ME, Crews DC, et al. Adherence to Healthy Dietary Patterns and Risk of CKD Progression and All-Cause Mortality: Findings From the CRIC (Chronic Renal Insufficiency Cohort) Study. *Am J Kidney Dis* 2021;77:235–44.

[31] Fulop T, Koch CA, Norris LT, Rodriguez B, Szarvas T, Lengvarszky Z, et al. Uric Acid Control in Advanced Chronic Kidney Disease in a Southeastern US Urban Cohort. *South Med J* 2018;111:549–55.

[32] Yanai H, Adachi H, Hakoshima M, Katsuyama H. Molecular Biological and Clinical Understanding of the Pathophysiology and Treatments of Hyperuricemia and Its Association with Metabolic Syndrome, Cardiovascular Diseases and Chronic Kidney Disease. *Int J Mol Sci* 2021;22.

[33] Zhang Y, He D, Zhang W, Xing Y, Guo Y, Wang F, et al. ACE Inhibitor Benefit to Kidney and Cardiovascular Outcomes for Patients with Non-Dialysis Chronic Kidney Disease Stages 3–5: A Network Meta-Analysis of Randomised Clinical Trials. *Drugs* 2020;80:797–811.

[34] Bhandari S, Mehta S, Khwaja A, Cleland JGF, Ives N, Brettell E, et al. Renin-Angiotensin System Inhibition in Advanced Chronic Kidney Disease. *N Engl J Med* 2022;387:2021–32.

[35] Koppe L, Fouque D. The Role for Protein Restriction in Addition to Renin-Angiotensin-Aldosterone System Inhibitors in the Management of CKD. *Am J Kidney Dis* 2019;73:248–57.

[36] Judd E, Calhoun DA. Management of hypertension in CKD: beyond the guidelines. *Adv Chronic Kidney Dis* 2015;22:116–22.

[37] Marqv DF, Ruiz-Hurtado G, Ruilope L. The impact of antihypertensives on kidney disease. *F1000Res* 2017;6:611.

[38] Bhandari S, Ives N, Brettell EA, Valente M, Cockwell P, Topham PS, et al. Multicentre randomized controlled trial of angiotensin-converting enzyme inhibitor/angiotensin receptor blocker withdrawal in advanced renal disease: the STOP-ACEi trial. *Nephrol Dial Transplant* 2016;31:255–61.

[39] Zeier M. ACE Inhibitors and ARB in Chronic Kidney Diseases: What Has to Be Considered. *Dtsch Med Wochenschr* 2018;143:880–5.

[40] Navis G, Faber HJ, de Zeeuw D, de Jong PE. ACE inhibitors and the kidney. A risk-benefit assessment. *Drug Saf* 1996;15:200–11.

[41] Leon SJ, Whitlock R, Rigatto C, Komenda P, Bohm C, Sucha E, et al. Hyperkalemia-Related Discontinuation of Renin-Angiotensin-Aldosterone System Inhibitors and Clinical Outcomes in CKD: A Population-Based Cohort Study. *Am J Kidney Dis* 2022;80:164–173 e161.

[42] Thanabalasingam S, Popa C, Arora N, Hiremath S, Teakell J. Renin-Angiotensin System Inhibitors in Advanced CKD: a #NephJC Editorial on STOP-ACEi. *Kidney Med* 2023;5:100633.

[43] Gooch K, Culleton BF, Manns BJ, Zhang J, Alfonso H, Tonelli M, et al. NSAID use and progression of chronic kidney disease. *Am J Med* 2007;120(280):e281–7.

[44] Zhang X, Donnan PT, Bell S, Guthrie B. Non-steroidal anti-inflammatory drug induced acute kidney injury in the community dwelling general population and people with chronic kidney disease: systematic review and meta-analysis. *BMC Nephrol* 2017;18:256.

[45] Baker M, Perazella MA. NSAIDs in CKD: Are They Safe? *Am J Kidney Dis* 2020;76:546–57.

[46] Guthrie B. Can NSAIDs Be Used Safely for Analgesia in Patients with CKD? *CON. Kidney360* 2020;1:1189–91.

[47] Davison SN. Clinical Pharmacology Considerations in Pain Management in Patients with Advanced Kidney Failure. *Clin J Am Soc Nephrol* 2019;14:917–31.

[48] Castaneda F, Burse A, Boland W, Kinne RK. Thioglycosides as inhibitors of hSGLT1 and hSGLT2: potential therapeutic agents for the control of hyperglycemia in diabetes. *Int J Med Sci* 2007;4:131–9.

[49] Hou YC, Zheng CM, Yen TH, Lu KC. Molecular Mechanisms of SGLT2 Inhibitor on Cardiorenal Protection. *Int J Mol Sci* 2020;21.

[50] Heerspink HJ, Perkins BA, Fitchett DH, Husain M, Cherney DZ. Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus: Cardiovascular and Kidney Effects, Potential Mechanisms, and Clinical Applications. *Circulation* 2016;134:752–72.

[51] Bonora BM, Avogaro A, Fadini GP. Extraglycemic Effects of SGLT2 Inhibitors: A Review of the Evidence. *Diabetes Metab Syndr Obes* 2020;13:161–74.

[52] Hasan I, Rashid T, Jaikaransingh V, Heilig C, Abdel-Rahman EM, Awad AS. SGLT2 inhibitors: Beyond glycaemic control. *J Clin Transl Endocrinol* 2024;35:100335.

[53] G. Nuffield Department of Population Health Renal Studies, S.i.M.-A.C.-R.T. Consortium, Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials, *Lancet* 400 (2022) 1788-1801.

[54] Butler J, Usman MS, Khan MS, Greene SJ, Friede T, Vaduganathan M, et al. Efficacy and safety of SGLT2 inhibitors in heart failure: systematic review and meta-analysis. *ESC Heart Fail* 2020;7:3298–309.

[55] Samms RJ, Coghlan MP, Sloop KW. How May GLP Enhance the Therapeutic Efficacy of GLP-1? *Trends Endocrinol Metab* 2020;31:410–21.

[56] Maselli DB, Camilleri M. Effects of GLP-1 and Its Analogs on Gastric Physiology in Diabetes Mellitus and Obesity. *Adv Exp Med Biol* 2021;1307:171–92.

[57] Nauck MA, Quast DR, Wefers J, Meier JJ. GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art. *Mol Metab* 2021;46:101102.

[58] Michos ED, Bakris GL, Rodbard HW, Tuttle KR. Glucagon-like peptide-1 receptor agonists in diabetic kidney disease: A review of their kidney and heart protection. *Am J Prev Cardiol* 2023;14:100502.

[59] Laurindo LF, Barbalho SM, Guiguer EL, da Silva Soares M, de Souza GA, de Souza TM, et al. Going beyond Traditional Use. *Int J Mol Sci* 2022;23.

[60] Epstein M, Kovesdy CP, Clase CM, Sood MM, Pecoits-Filho R. Aldosterone, Mineralocorticoid Receptor Activation, and CKD: A Review of Evolving Treatment Paradigms. *Am J Kidney Dis* 2022;80:658–66.

[61] Fukuda S, Horimai C, Harada K, Wakamatsu T, Fukasawa H, Muto S, et al. Aldosterone-induced kidney injury is mediated by NFκappaB activation. *Clin Exp Nephrol* 2011;15:41–9.

[62] Lopez-Andres N, Martin-Fernandez B, Rossignol P, Zannad F, Lahera V, Fortuno MA, et al. A role for cardiotrophin-1 in myocardial remodeling induced by aldosterone. *Am J Physiol Heart Circ Physiol* 2011;301:H2372–82.

[63] Barrera-Chimal J, Gierd S, Jaisser F. Mineralocorticoid receptor antagonists and kidney diseases: pathophysiological basis. *Kidney Int* 2019;96:302–19.

[64] Rossing P, Filippatos G, Agarwal R, Anker SD, Pitt B, Ruilope LM, et al. Finerenone in Predominantly Advanced CKD and Type 2 Diabetes With or Without Sodium-Glucose Cotransporter-2 Inhibitor Therapy. *Kidney Int Rep* 2022;7:36–45.

[65] Adamczak M, Surma S. Metabolic Acidosis in Patients with CKD: Epidemiology, Pathogenesis, and Treatment. *Kidney Dis (Basel)* 2021;7:452–67.

[66] de Brito-Ashurst I, Varagunam M, Rafferty MJ, Yaqoob MM. Bicarbonate supplementation slows progression of CKD and improves nutritional status. *J Am Soc Nephrol* 2009;20:2075–84.

[67] Madias NE. Metabolic Acidosis and CKD Progression. *Clin J Am Soc Nephrol* 2021;16:310–2.

[68] Kovesdy CP. Metabolic acidosis and kidney disease: does bicarbonate therapy slow the progression of CKD? *Nephrol Dial Transplant* 2012;27:3056–62.

[69] J.A. Kraut, G.T. Nagami, *Metabolic Acidosis and Chronic Kidney Disease*.

[70] Samlaka CP, Winfield EA. Pentoxifylline. *J Am Acad Dermatol* 1994;30:603–21.

[71] de Moraes AM, Goicoechea M, Verde E, Carbayo J, Barbieri D, Delgado A, et al. Pentoxifylline, progression of chronic kidney disease (CKD) and cardiovascular mortality: long-term follow-up of a randomized clinical trial. *J Nephrol* 2019;32:581–7.

[72] Jiang X, Zhou S, Yao J, Kong X, Cui M. Effect of pentoxifylline in proteinuric chronic kidney disease: a systematic review and meta-analysis. *J Nephrol* 2016;29:653–62.

[73] Lin SL, Chiang WC, Chen YM, Lai CF, Tsai TJ, Hsieh BS. The renoprotective potential of pentoxifylline in chronic kidney disease. *J Chin Med Assoc* 2005;68:99–105.

[74] Chen YM, Chiang WC, Lin SL, Tsai TJ. Therapeutic efficacy of pentoxifylline on proteinuria and renal progression: an update. *J Biomed Sci* 2017;24:84.

[75] Atkinson MA, Warady BA. Anemia in chronic kidney disease. *Pediatric nephrology (Berlin, Germany)* 2018;33:227–38.

[76] Hanna RM, Streja E, Kalantar-Zadeh K. Burden of Anemia in Chronic Kidney Disease: Beyond Erythropoietin. *Adv Ther* 2021;38:52–75.

[77] Gafter-Gvili A, Schechter A, Rozen-Zvi B. Iron Deficiency Anemia in Chronic Kidney Disease. *Acta Haematol* 2019;142:44–50.

[78] De Franceschi L, Iolascon A, Taher A, Cappellini MD. Clinical management of iron deficiency anemia in adults: Systemic review on advances in diagnosis and treatment. *Eur J Intern Med* 2017;42:16–23.

[79] Macdougall IC. Anaemia in CKD-treatment standard. *Nephrol Dial Transplant* 2024;39:770–7.

[80] Natale P, Palmer SC, Jaure A, Hodson EM, Ruospo M, Cooper TE, et al. Hypoxia-inducible factor stabilisers for the anaemia of chronic kidney disease. *Cochrane Database Syst Rev* 2022;8:CD013751.

[81] A.K. Singh, K. Carroll, V. Perkovic, S. Solomon, V. Jha, K.L. Johansen, R.D. Lopes, I. C. Macdougall, G.T. Obrador, S.S. Waikar, C. Wanner, D.C. Wheeler, A. Wiecek, A. Blackorby, B. Cizman, A.R. Cobitz, R. Davies, J. Dole, L. Kler, A.M. Meadowcroft, X. Zhu, J.J.V. McMurray, A.-D.S. Group, *Daprodustat for the Treatment of Anemia in Patients Undergoing Dialysis*, *N Engl J Med* 385 (2021) 2325-2335.

[82] Akizawa T, Otsuka T, Reusch M, Ueno M. Intermittent Oral Dosing of Roxadustat in Peritoneal Dialysis Chronic Kidney Disease Patients with Anemia: A Randomized, Phase 3, Multicenter, Open-Label Study. *Ther Apher Dial* 2020;24:115–25.

[83] Fishbane S, Spinowitz B. Update on Anemia in ESRD and Earlier Stages of CKD: Core Curriculum 2018. *Am J Kidney Dis* 2018;71:423–35.

[84] Cannata-Andia JB, Martin-Carro B, Martin-Virgala J, Rodriguez-Carrio J, Bande-Fernandez JJ, Alonso-Montes C, et al. Chronic Kidney Disease-Mineral and Bone Disorders: Pathogenesis and Management. *Calcif Tissue Int* 2021;108:410–22.

[85] Portillo MR, Rodriguez-Ortiz ME. Secondary Hyperparathyroidism: Pathogenesis, Diagnosis, Preventive and Therapeutic Strategies. *Rev Endocr Metab Disord* 2017;18:79–95.

[86] Hruska KA, Sugatani T, Agapova O, Fang Y. The chronic kidney disease - Mineral bone disorder (CKD-MBD): Advances in pathophysiology. *Bone* 2017;100:80–6.

[87] Isakova T, Nickolas TL, Denburg M, Yarlagadda S, Weiner DE, Gutierrez OM, et al. KDIGO Clinical Practice Guideline Update for the Diagnosis, Evaluation,

- Prevention, and Treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). *Am J Kidney Dis* 2017;70(2017):737–51.
- [88] Khairallah P, Nickolas TL. Management of Osteoporosis in CKD. *Clin J Am Soc Nephrol* 2018;13:962–9.
- [89] Sridharan K. Chronic kidney disease mineral and bone disorder: A guide for general practice. *Aust J Gen Pract* 2023;52:52–7.
- [90] Fulop T, Koch CA, Farah Musa AR, Clark CM, Gharaibeh KA, Lengvarsky Z, et al. Targeted surgical parathyroidectomy in end-stage renal disease patients and long-term metabolic control: A single-center experience in the current era. *Hemodial Int* 2018;22:394–404.
- [91] Gopaul A, Kanagalingam T, Thain J, Khan T, Cowan A, Sultan N, et al. Denosumab in chronic kidney disease: a narrative review of treatment efficacy and safety. *Arch Osteoporos* 2021;16:116.
- [92] Hu L, Napoletano A, Provenzano M, Garofalo C, Bini C, Comai G, et al. Mineral Bone Disorders in Kidney Disease Patients: The Ever-Current Topic. *Int J Mol Sci* 2022;23.
- [93] Iseri K, Mizobuchi M, Winzenrieth R, Humbert L, Saitou T, Kato T, et al. Long-Term Effect of Denosumab on Bone Disease in Patients with CKD. *Clin J Am Soc Nephrol* 2023;18:1195–203.